Journal of Modern OncologyJournal of Modern Oncology1815-14341815-1442LLC Obyedinennaya Redaktsiya27127Research ArticleThe results of the treatment of patients with advanced hepatocellular carcinoma in Sverdlovsk regionPetkauV Vvpetkau@yandex.ruTarkhanovA A-KiselevE A-Ural State Medical University of the Ministry of Health of the Russian FederationSverdlovsk Regional Oncology Dispensary15012017191757909042020Copyright © 2017, Consilium Medicum2017The aim is to assess treatment outcomes of patients with advanced hepatocellular cancer (HCC) in daily clinical practice through the example of SHI Sverdlovsk Regional Oncology Dispensary. Materials and methods. The data of regional cancer registry, annual reports of SHI SROD and HCC patients’ medical records were retrospectively studied. 542 patients with stage III and stage IV primary liver cancer applied to outpatient department of SHI SROD in the period of 2011 to 2015. Morphological verification was received in 53 (9.8%) patients. These patients received antitumor treatment: surgery, transarterial chemoembolization (TACE), sorafenib therapy, chemotherapy and the combination of these methods. We examined median overall survival (OS) based on the stage of the process and on tactics. Results. The incidence of malignant neoplasms of the liver has increased in the Sverdlovsk Region over the past 5 years: from 5.58 to 7.6 cases per 100 000 population in men and from 4.93 to 5.1 - in women. Mortality rate has remained at the same level. We determined 82% of patients with stage III and IV HCC. Patients with intermediate-stage (stage B) HCC (n = 21) according to the Barcelona Clinical Liver Cancer staging system underwent surgery (10 patients) or TACE and doxorubicin (11 patients). Median OS was 20.7 and 13.3 months, respectively. Patients with advanced-stage (stage C) HCC (n=32) had undergone surgery before the start of sorafenib therapy (6 patients), TACE (8 patients), TACE plus sorafenib therapy (4 patients) and only sorafenib therapy (4 patients) or cytostatic systemic therapy (10 patients). Median OS was minimum (5.3 months) in the group of patients who had received only chemotherapy. Median OS was maximum (18 months) in sorafenib-treated patients and in patients who had undergone surgery. Conclusions. More than 80% of patients with stage III or IV HCC and with poor general condition usually apply to hospital and thus limiting the possibility of further antitumor treatment. The best approaches to the management of patients with advanced HCC are the combination of methods associated with local effect (surgical treatment and/or TACE) and systemic therapy using such drug as sorafenib.hepatocellular carcinomasorafenibchemoembolizationгепатоцеллюлярный раксорафенибхимиоэмболизация[Mc Glynn K.A, London W.T. The Global Epidemiology of Hepatocellular Carcinoma, Present and Future. Clin Liver Dis 2011 May; 15 (2): 223-45.][Mittal S, El-Serag H.B. Epidemiology of HCC: Consider the Population. J Clin Gastroenterol 2013; 47(0): s2-s6.][Петрова Г.В., Каприн А.Д., Грецова О.П., Старинский В.В. Злокачественные новообразования в России обзор статистической информации за 1993-2013 гг. М.: МНИОИ им. П.А.Герцена филиал ФГБУ НМИРЦ Минздрава России, 2015; с. 511.][Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году (заболеваемость и смертность). М.: МНИОИ им. П.А.Герцена филиал ФГБУ НМИРЦ Минздрава России, 2017; с. 250.][Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2015 году. М.: МНИОИ им. П.А.Герцена филиал ФГБУ НМИРЦ Минздрава России, 2016; с. 236.][Llovet J.M, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.][Johnson P.J, Berhane S, Kagebayashi C et al. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence - Based Approach - The ALBI Grade. J Clin Oncol 2015; 33 (2): 550-8.][Llovet J.M, Bruix J. Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 32 (3): 679-80.][Takayama T. Surgical Treatment for Hepatocellular Carcinoma. Jpn J Clin Oncol 2011; 41(4): 447-54.][Lencioni R. Loco - regional treatment of hepatocellular carcinoma. Hepatology 2010; 52: 762-73.][Knox J.J, Cleary S.P, Dawson L.A. Localized and Systemic Approaches to Treating Hepatocellular Carcinoma. J Clin Oncol 2015; 33 (6): 1835-44.][Takayasu K. Transarterial Chemoembolization for Hepatocellular Carcinoma over Three Decades: Current Progress and Perspective. Jpn J Clin Oncol 2012; 42 (4): 247-55.][Yeo W, Mok T.S, Zee B et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005; 97: 1532-8.][Boige V, Raoul J.L, Pignon J.P et al. Federation Francophone de Cancérologie Digestive. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007; 97: 862-67.][Louafi S, Boige V, Ducreux M et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 2007; 109: 1384-90.][Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow - up. Annals of Oncology 2012; 23 (Suppl. 7): vii41-vii48.][Практические рекомендации по лекарственному лечению злокачественных опухолей (RUSSCO) под редакцией В.М.Моисеенко. М.: Российское общество клинической онкологии, 2015; с. 456.][Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.][Park J.W, Chen M, Colombo M et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver International 2015; 35: 2155-66.][Marrero J, Lencioni R, Ye S.L et al. Final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) in >3000 sorafenib - treated patients: clinical findings in patients with liver dysfunction. Poster presented at the Annual Meeting of the American Society of Clinical Oncology, May 31 - June 4, 2013. Chicago, Illinois, USA.]